Pfizer's decision to pump the brakes on COVID vaccines for kids younger than 5 was a good call, experts tell Axios.
Driving the news: Pfizer decided not to seek an FDA authorization until it has more data about how well its vaccine works after three doses. An FDA committee had been slated to consider the data for a two-dose regimen next week.
